Overexpression of MALT1-A20-NF-κB in adult B-cell acute lymphoblastic leukemia

[1]  H. Kantarjian,et al.  Acute lymphoblastic leukemia in adolescents and young adults , 2017, Cancer.

[2]  Xu Wang,et al.  Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia , 2014, European Journal of Medical Research.

[3]  S. Barta,et al.  New antibody approaches to lymphoma therapy , 2014, Journal of Hematology & Oncology.

[4]  W. Carroll,et al.  The Biology of Relapsed Acute Lymphoblastic Leukemia: Opportunities for Therapeutic Interventions , 2014, Journal of pediatric hematology/oncology.

[5]  M. Prinz,et al.  Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis , 2014, Journal of Neuroinflammation.

[6]  J. Rowe,et al.  Pathogenesis and prognostication in acute lymphoblastic leukemia , 2014, F1000prime reports.

[7]  Xu Wang,et al.  Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia , 2014, Experimental Hematology & Oncology.

[8]  Jennifer S. Woo,et al.  Childhood B-acute lymphoblastic leukemia: a genetic update , 2014, Experimental Hematology & Oncology.

[9]  Xu Wang,et al.  Abnormal expression of A20 and its regulated genes in peripheral blood from patients with lymphomas , 2014, Cancer Cell International.

[10]  D. Reece,et al.  Bortezomib in multiple myeloma: systematic review and clinical considerations. , 2014, Current oncology.

[11]  Xiuli Wu,et al.  Gene expression pattern of Treg and TCR Vγ subfamily T cells before and after specific immunotherapy in allergic rhinitis , 2014, Journal of Translational Medicine.

[12]  A. Melnick,et al.  Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma , 2013, Clinical Cancer Research.

[13]  Maria Braoudaki,et al.  Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner , 2013, Journal of Hematology & Oncology.

[14]  He Huang,et al.  Novel agents and biomarkers for acute lymphoid leukemia , 2013, Journal of Hematology & Oncology.

[15]  Xu Wang,et al.  Changes in the MALT1-A20-NF-κB expression pattern may be related to T cell dysfunction in AML , 2013, Cancer Cell International.

[16]  Ming Wang,et al.  Bladder Polypoid Cystitis-Derived A20 Associates with Tumorigenesis , 2013, Cell Biochemistry and Biophysics.

[17]  R. Gascoyne,et al.  MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. , 2012, Cancer cell.

[18]  Li-jian Yang,et al.  The role of A20 in the pathogenesis of lymphocytic malignancy , 2012, Cancer Cell International.

[19]  A. Ma,et al.  A20: linking a complex regulator of ubiquitylation to immunity and human disease , 2012, Nature Reviews Immunology.

[20]  Zi-yu Liu,et al.  Expression of A20 is reduced in pancreatic cancer tissues , 2012, Journal of Molecular Histology.

[21]  Fenggui Wei,et al.  Targeting A20 enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells. , 2012, Biochemical and biophysical research communications.

[22]  Xiuli Wu,et al.  Granulocyte colony-stimulating factor affects the distribution and clonality of TRGV and TRDV repertoire of T cells and graft-versus-host disease , 2011, Journal of Translational Medicine.

[23]  W Sterry,et al.  Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome , 2011, Leukemia.

[24]  C. Plass,et al.  Sustained NF‐kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus , 2011, International journal of cancer.

[25]  A. Chott,et al.  TNFAIP3 abnormalities in MALT lymphoma with autoimmunity , 2011, British journal of haematology.

[26]  Rudi Beyaert,et al.  Expression, biological activities and mechanisms of action of A20 (TNFAIP3). , 2010, Biochemical pharmacology.

[27]  J. M. Kim,et al.  Novel anti-apoptotic mechanism of A20 through targeting ASK1 to suppress TNF-induced JNK activation , 2010, Cell Death and Differentiation.

[28]  Roger E. McLendon,et al.  Targeting A20 Decreases Glioma Stem Cell Survival and Tumor Growth , 2010, PLoS biology.

[29]  H. Tagawa,et al.  TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. , 2009, Blood.

[30]  G. van Loo,et al.  The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. , 2009, Trends in immunology.

[31]  Tianbing Ding,et al.  A20 is overexpressed in glioma cells and may serve as a potential therapeutic target , 2009, Expert opinion on therapeutic targets.

[32]  S. Ogawa,et al.  Frequent inactivation of A20 in B-cell lymphomas , 2009, Nature.

[33]  L. Pasqualucci,et al.  The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. , 2008, Blood.

[34]  P. Marynen,et al.  T cell antigen receptor stimulation induces MALT1 paracaspase–mediated cleavage of the NF-κB inhibitor A20 , 2008, Nature Immunology.

[35]  C. Dumontet,et al.  A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells , 2007, Oncogene.

[36]  L. Recht,et al.  Tumor Necrosis Factor-α–Induced Protein 3 As a Putative Regulator of Nuclear Factor-κB–Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas , 2006 .

[37]  R. Beyaert,et al.  A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. , 2000, Biochemical pharmacology.

[38]  J. Salisbury,et al.  A20 RNA expression is associated with undifferentiated nasopharyngeal carcinoma and poorly differentiated head and neck squamous cell carcinoma , 1999, The Journal of pathology.

[39]  D. Goeddel,et al.  The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Jäättelä,et al.  A20 zinc finger protein inhibits TNF and IL-1 signaling. , 1996, Journal of immunology.

[41]  A. Krikos,et al.  Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. , 1992, The Journal of biological chemistry.

[42]  V. Dixit,et al.  The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. , 1992, The Journal of biological chemistry.

[43]  C. Ferran,et al.  A20--an omnipotent protein in the liver: prometheus myth resolved? , 2014, Advances in experimental medicine and biology.

[44]  L. Recht,et al.  Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.